MedTrace Logo

A Study Of Three PF-05190457 Formulations In Healthy Volunteers

NCT01522807 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2012-02-01

No results posted yet for this study

Summary

The purpose of the study is to evaluate the plasma drug concentrations of three formulations of PF-05190457 after administration of single doses to healthy volunteers.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

PF-05190457

100 mg single oral dose of PF-05190457 is administered as a suspension in the fasted state

DRUG

PF-05190457

100 mg single oral dose of PF-05190457 is administered as a short-duration osmotic capsule in the fasted state

DRUG

PF-05190457

100 mg single oral dose of PF-05190457 is administered as a long-duration osmotic capsule in the fasted state

DRUG

PF-05190457

100 mg single oral dose of PF-05190457 is administered as a short-duration osmotic capsule in the fed state

DRUG

PF-05190457

100 mg single oral dose of PF-05190457 is administered as a suspension in the fasted state

DRUG

PF-05190457

100 mg single oral dose of PF-05190457 is administered as a short-duration osmotic capsule in the fasted state

DRUG

PF-05190457

100 mg single oral dose of PF-05190457 is administered as a long-duration osmotic capsule in the fasted state

DRUG

PF-05190457

100 mg single oral dose of PF-05190457 is administered as a long-duration osmotic capsule in the fed state

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2011-11-30
Completion
2011-11-30

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01522807 on ClinicalTrials.gov